Monitoring cirrhosis between hospital visits is one of the hardest problems in hepatology. Patients leave the hospital feeling better, then fluid builds, confusion creeps in, and many are back within weeks. Remote patient monitoring (RPM) gives care teams a way to see those changes while there is still time to act. This article looks at the facts behind cirrhosis, the research on monitoring cirrhosis with RPM, and what a home monitoring program for liver disease actually tracks.
Cirrhosis Facts and Why Monitoring Cirrhosis Matters
Cirrhosis is advanced scarring of the liver. It develops after years of damage from hepatitis, alcohol use, metabolic liver disease, or other causes. Scar tissue cannot be reversed. Early diagnosis and treatment of the underlying cause can slow further damage, which is why monitoring cirrhosis matters so much once it is found.
The CDC reports that 4.5 million U.S. adults, or 1.8 percent, have diagnosed liver disease. Chronic liver disease and cirrhosis caused 52,274 deaths in 2024. That is a rate of 15.4 deaths per 100,000 people. Liver disease is becoming more common as metabolic disease and alcohol-related liver disease rise.
Cirrhosis is often silent until the damage is severe. When symptoms appear, they can include:
- Jaundice, a yellow tint to the skin and eyes
- Ascites, fluid buildup in the abdomen
- Edema, swelling in the legs, feet, or ankles
- Fatigue and loss of appetite
- Nausea and unexplained weight loss
- Easy bleeding or bruising
- Itchy skin
- Confusion or drowsiness, a sign of hepatic encephalopathy
Several of these symptoms are measurable at home. Fluid shows up on a scale before a patient notices it. Infection often starts with a fever. Confusion can be caught with a short cognitive check. That is the opening remote monitoring works through.
Why Hospital Readmissions Drive the Need for Monitoring Cirrhosis
Readmission is the clearest sign that outpatient care for cirrhosis falls short. A systematic review of 26 studies found 30-day readmission rates from 10 to 50 percent, with a pooled estimate of 26 percent. Ninety-day readmissions ranged from 21 to 71 percent. A nationwide analysis of 57,305 patients with decompensated cirrhosis put the 30-day readmission rate at 23 percent, at a total cost of about $234 million.
The cost falls on patients and the system alike. A Mayo Clinic cohort of 2,048 hospitalized patients with cirrhosis found a 30-day readmission rate of 32 percent. Annual costs after the index stay were $73,252 for patients readmitted within 30 days, compared with $5,719 for those not readmitted. Most readmissions were for complications of portal hypertension and infection. Both tend to signal themselves before they become emergencies.
Cirrhosis is not yet in the CMS Hospital Readmissions Reduction Program, but health systems are already treating it as a readmission priority. Tenovi’s guide to hospital readmissions covers how remote monitoring fits that work across conditions.
What Remote Patient Monitoring for Cirrhosis Tracks
Monitoring cirrhosis at home focuses on a short list of signals tied to the most common reasons for readmission. A typical program collects:
- Daily weight. Rapid gain points to ascites or edema. Rapid loss can signal poor nutrition or overdiuresis.
- Blood pressure and heart rate. Low pressure or a fast pulse can precede bleeding, infection, or kidney injury.
- Temperature. Fever is an early sign of spontaneous bacterial peritonitis and other infections.
- Oxygen saturation. Useful in patients with hepatopulmonary complications or fluid in the chest.
- Symptom questionnaires. Abdominal girth, swelling, bowel movements, and sleep changes help track ascites and encephalopathy.
- Cognitive checks. Short app-based tests can flag early hepatic encephalopathy before a family member notices confusion.
- Medication adherence. Lactulose and diuretic adherence is a common gap, and missed doses often precede readmission.
Weight is the backbone of most programs because it is passive and objective. Tenovi’s post on the connected weight scale explains how daily readings catch fluid retention before symptoms appear.
Research on Monitoring Cirrhosis with RPM: The CiRPM Program
A study published in Hepatology Communications in 2024 described a cirrhosis-specific remote patient monitoring program called CiRPM. Forty-six patients with decompensated cirrhosis were offered enrollment at hospital discharge. Forty-one completed at least 30 days of monitoring, with an average of about 84 days. Patients were mailed monitoring equipment and a tablet for reporting symptoms. Alerts fired when readings or answers crossed predefined thresholds, which allowed remote management of hepatic encephalopathy and ascites.
Key results from the study:
- Participants uploaded vital signs or questionnaire answers on 93 percent of monitored days.
- 88 percent of participants completed their tasks on at least 85 percent of days.
- More than 75 percent of surveyed patients were satisfied with the program.
- The 90-day readmission rate was 34 percent in CiRPM versus 47 percent in weighted controls.
- 12 percent of CiRPM patients had two or more readmissions, compared with 37 percent of controls.
- Potentially preventable readmissions were 36 percent in CiRPM versus 57 percent in controls.
The trends toward fewer readmissions and lower mortality did not reach statistical significance. The authors were careful on that point. What the study did establish is that monitoring cirrhosis with RPM is feasible, that patients will use it, and that engagement stays high over months. They offered the program design as a roadmap for other liver centers.
CirrhoCare: From Pilot Study to Randomized Trial
CirrhoCare is a digital monitoring and management system developed in the United Kingdom for patients at risk of acute decompensation. A 2023 pilot study from University College London, published in the Journal of Hepatology, tested it in 20 patients with advanced cirrhosis, most with alcohol-related disease, matched to 20 controls. The kit included a smartwatch, a blood pressure cuff, and a bioimpedance scale, paired with a smartphone app that tracked weight, fluid and alcohol intake, cognition, and well-being.
Over roughly 10 weeks, 15 of 20 patients used the app at least four times per week. Five CirrhoCare patients had eight readmissions, with a median stay of five days and none longer than two weeks. The control group saw 13 readmissions among eight patients, four of which lasted more than two weeks. Clinicians made 16 contacts with patients based on CirrhoCare data. The monitored group needed one unplanned paracentesis compared with six in the control group.
That pilot led to a much larger test. A multicentre randomized controlled trial protocol was published in BMJ Open in July 2025. The trial will enroll 214 patients across at least 12 UK centres, randomized to CirrhoCare or standard care after discharge for acute decompensation. The primary outcome is hospital interventions over 12 weeks, mainly readmissions. The trial will also measure cost-effectiveness, quality of life, and barriers to real-world use. Results are expected to give hepatology its first powered answer on whether remote monitoring changes outcomes in cirrhosis.
What Newer Studies Say About Monitoring Cirrhosis
Two 2025 publications help put the field in context.
A systematic review in Hepatology Communications screened more than 17,000 records and identified 12 studies of remote monitoring in cirrhosis, covering 636 patients. Only one was a randomized controlled trial. The authors found clinical benefit across studies but noted wide variation in interventions, design, and outcomes. They called for agreement on monitoring frameworks and higher-quality trials so clinicians can make better decisions.
A separate prospective cohort enrolled 119 patients with cirrhosis between 2023 and 2025 and tracked adherence to a commercial wearable. Data completeness was above 95 percent on collected days. Median full adherence was about 66 percent of eligible days. Sociodemographic factors did not predict adherence. Patients with decompensated disease or Child-Pugh B or C did wear the device less, which suggests that the sickest patients need extra support to stay engaged.
The pattern across all of this research is consistent. Patients with cirrhosis will take part in remote monitoring. Early detection of fluid, fever, and confusion appears to shorten and reduce hospital stays. The missing piece is a large randomized trial, and that trial is now underway.
Building a Program for Monitoring Cirrhosis at Home
The research points to a few practical lessons for care teams and the RPM companies that support them.
Keep the device burden low. CirrhoCare and CiRPM both mailed kits and trained patients before discharge. Devices that work out of the box, without a phone or Wi-Fi, remove the most common reason readings go missing. Devices paired through a cellular hub like the Tenovi Gateway send data on their own once the patient steps on a scale or takes a reading.
Set thresholds for the signals that matter. A defined weight gain over one to three days, a fever, a drop in blood pressure, or a failed cognitive check should trigger a call. The value is in the response, not the reading.
Watch for silence. A patient who stops weighing in may be too unwell to keep up. Programs should treat missed readings as an alert.
Plan for the sickest patients. Adherence falls as disease severity rises. Extra outreach in the first weeks after discharge is where it pays off most.
Think across organs. Cirrhosis often travels with kidney injury and heart disease. The same scale and blood pressure cuff support kidney monitoring and cardiac care, so one program can cover several risks.
Frequently Asked Questions About Monitoring Cirrhosis
These questions come up often from care teams and RPM program managers who are considering monitoring cirrhosis with remote devices. The answers below draw on the studies described above.
1) What vital signs are most useful for monitoring cirrhosis at home?
Daily weight is the most useful single measure because it reflects fluid balance. Temperature, blood pressure, and heart rate add early warning for infection, bleeding, and kidney injury. Symptom and cognition questionnaires round out the picture for ascites and hepatic encephalopathy.
2) Can remote patient monitoring reduce readmissions for cirrhosis?
The evidence is encouraging but not yet definitive. CiRPM showed a 90-day readmission rate of 34 percent versus 47 percent in controls, and the CirrhoCare pilot saw fewer and shorter readmissions. Neither was powered to prove the effect. A 214-patient randomized trial is now testing the question directly.
3) Will patients with cirrhosis actually use remote monitoring?
Yes, in most studies. CiRPM participants uploaded data on 93 percent of monitored days. A 2025 wearable cohort found high data quality and moderate-to-high adherence. Patients with more advanced disease used devices less and may need more support.
4) How does monitoring cirrhosis help with hepatic encephalopathy?
Encephalopathy often starts subtly, with changes in sleep, attention, or handwriting. App-based cognitive checks and caregiver questionnaires can catch those changes early. Care teams can then adjust lactulose or rifaximin before confusion leads to a hospital visit.
5) What equipment does a cirrhosis monitoring program need?
A connected weight scale and a blood pressure monitor are the core. A thermometer and pulse oximeter are common additions. A tablet or app handles questionnaires and cognition tests. Cellular-connected devices avoid the need for a smartphone or home internet.
6) Is remote monitoring for cirrhosis covered by Medicare?
Remote patient monitoring is a covered Medicare service when it meets CMS requirements for device type, data days, and clinical management time. Coverage is not condition-specific, so cirrhosis programs can qualify. Billing providers should confirm current requirements with CMS and their payers.
Understanding Monitoring Cirrhosis with Remote Patient Monitoring
Cirrhosis affects millions of Americans and carries one of the highest readmission rates of any chronic condition. Most of those readmissions follow signals that show up at home first: fluid gain on a scale, a fever, a change in thinking. Monitoring cirrhosis with remote patient monitoring puts those signals in front of a care team every day. The CiRPM program and the CirrhoCare pilot both showed high engagement and fewer, shorter hospital stays. A 2025 systematic review found consistent benefit but called for stronger trials, and a 214-patient randomized study is now underway to provide that evidence. For care teams, the practical path is clear. Keep devices simple, set thresholds for the signals that matter, and support the sickest patients closely in the weeks after discharge.
Tenovi provides the cellular-connected device infrastructure behind remote patient monitoring and remote therapeutic monitoring programs for RPM software companies, chronic care management providers, health systems, and payers. Our connected scales, blood pressure monitors, thermometers, and pulse oximeters send readings through the Tenovi Gateway without a phone or Wi-Fi, so data arrives reliably from the patients who need watching most. To see how Tenovi can support a liver disease monitoring program, request a free demo and consultation.
